Altimmune Inc.

Altimmune highlighted a broad range of target indications for its “pipeline-in-a-product” candidate pemvidutide in a 13 March R&D Day presentation for investors and analysts that could expand the

For big pharma companies who want a major stake in the ballooning obesity market, opportunities to license in a mid-stage asset are dwindling. Roche claimed one of the top unlicensed candidates on 12

Looking ahead to 2025, industry leaders shared their insights into the key trends and topics they expect to see. Click on topic headings to read executive predictions. The insights in this article hav

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office